Test Price
2,800 AED✅ Home Collection Available
SLC35A1 Gene (CDG IIF) Next‑Generation Sequencing Genetic Test in UAE
Executive Summary & Core Metrics
Executive Summary: The SLC35A1 gene sequencing test using Next‑Generation Sequencing (NGS) is a high‑precision diagnostic tool for detecting Congenital Disorder of Glycosylation Type IIF (CDG IIF). This analysis, accredited by DHA under ISO 9001:2015, delivers the highest quality and reliability standards, supported by VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection for peripheral blood specimens and specialized post‑test clinical guidance.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced NGS test sequences the entire coding region of the SLC35A1 gene to detect pathogenic variants causing Congenital Disorder of Glycosylation Type IIF, a rare neurodevelopmental condition with multi‑system involvement. The high‑throughput platform ensures comprehensive coverage of all coding exons and intronic boundaries, enabling the identification of novel and known mutations that traditional Sanger sequencing frequently misses.
Our clinically curated bioinformatics pipeline follows current ACMG guidelines, classifying variants according to standardized pathogenicity criteria. Results are correlated with clinical phenotype and family history to guide precise management strategies, including targeted therapy and surveillance planning for affected individuals.
| Feature | Our NGS Test (CDG IIF) | Traditional Sanger Sequencing |
|---|---|---|
| Methodology | Next‑Generation Sequencing (high‑throughput, full‑gene coverage) | Single‑exon capillary electrophoresis |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Mutation Detection Rate | >99% of coding variants including deep intronic signals | ~80%, misses novel or non‑targeted mutations |
| Cost | 2800 AED | Often higher when multiple exons are tested individually |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I fully appreciate the complex emotions families experience when pursuing genetic testing for rare neurodevelopmental disorders. The SLC35A1 NGS test offers definitive molecular clarification, yet results must always be interpreted alongside comprehensive clinical evaluation, family pedigree analysis, and biochemical glycosylation studies. Never alter pharmacological regimens based solely on genomic findings without direct oversight from your treating physician and genetic counsellor.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Precautions
⚠️ Medication Warning
Do not discontinue or modify any prescribed medication without explicit consultation with your doctor. Genetic findings are designed to inform, not replace, ongoing clinical care. Always present your complete report to a qualified physician for integrated treatment planning.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active febrile illness, severe coagulopathy, or inability to provide informed consent. Minors require a legal guardian’s consent in accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- Emergency Red Flags: If you experience syncope, persistent bleeding, or signs of infection at the phlebotomy site, seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What does SLC35A1 genetic testing diagnose?
This test identifies pathogenic variants in the SLC35A1 gene that cause Congenital Disorder of Glycosylation Type IIF, a rare neurodevelopmental disorder with multi‑system involvement. It is essential for confirming clinical suspicion in children and adults presenting with unexplained psychomotor delay, hypotonia, coagulopathy, or seizures related to glycosylation defects. Early molecular diagnosis enables targeted surveillance, therapy, and genetic counselling for families.
2. Why choose NGS over older genetic testing methods?
NGS comprehensively reads all coding exons and flanking intronic regions, ensuring high sensitivity for novel and mosaic mutations that conventional Sanger sequencing may miss. Our validated pipeline aligns with current ACMG guidelines and uses clinically curated databases, significantly reducing inconclusive results. This approach accelerates the diagnostic odyssey and enables faster targeted management and therapeutic intervention.
3. How long do results take and what does the report include?
Results are delivered in 3–4 weeks from sample receipt. The final report includes a detailed variant interpretation with pathogenicity classification per ACMG criteria, relevant OMIM references, in silico prediction scores, and clinical correlation recommendations for the treating physician. Your neurologist or genetic counsellor can use this comprehensive data to tailor surveillance, therapy, and family cascade testing.
4. Is home sample collection available for this genetic test?
Yes. For standard peripheral whole blood specimens, our VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection service is available daily from 8 AM to 11 PM. A certified nurse will visit your home, collect the sample under sterile conditions, and transport it directly to our ISO‑accredited laboratory for processing.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This service strictly adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed in compliance with DHA/MOHAP standards. Clinical safety and patient consent follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | SLC35A1 Gene (CDG IIF) Next‑Generation Sequencing Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Coding Region & Intronic Boundaries |
| ICD-10-CM Code | E77.8 |
| LOINC Code | 79231-5 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians